The KATE2 phase II trial compared the safety and efficacy of T-DM1 alone or in combination with atezolizumab in HER2-positive patients with locally advanced BC who received prior trastuzumab and taxane therapy. This evidence concerns the gene ERBB2 and breast cancer.